Leading by example



Dow Jones Sustainability Emerging Markets Index 2019

Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row


Making advances in Respiratory

Glenmark’s leading respiratory pipeline candidate Ryaltris™, formerly GSP 301 Nasal Spray, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, accepted by the US FDA for review as a treatment for seasonal allergic rhinitis.


Innovating in respiratory

Ryaltris (formerly GSP 301 Nasal Spray), a combination steroid plus antihistamine nasal spray for the treatment of allergic rhinitis, has completed three Phase 3 trials and is preparing for an NDA submission in CY 18.


Providing differentiated generics products

Glenmark launched ezetimibe, the first and only generic version of Zetia® in the United States for the treatment of high cholesterol.


Advancing oncology portfolio

With the addition of GBR 1372, a bispecific monoclonal antibody from Glenmarks’s BEAT® technology platform, Glenmark has three clinical candidates targeting oncology indications.


Making respiratory a focus area

Glenmark announced the Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. In the same year, Glenmark received approval for generic Seretide in Russia.


Expanded manufacturing operations – US and Switzerland

Glenmark commissioned a new manufacturing facility in North Carolina, US for development of injectable and oral solid dosages.

In the same year, Glenmark also set up a new antibody manufacturing facility in La Chaux-de-Fonds, Switzerland for development of clinical GMP-grade biologics for clinical trials.


Out-licensing deal with Forest Labs

Glenmark entered into an out-licensing deal with Forest Labs for its novel molecule targeting mPGES-1 Inhibitor. Glenmark received USD 15 Mn payment from Forest Labs on an option agreement


Out-licensing of first novel biological entity GBR 500

  • Glenmark out-licensed its first novel biological entity GBR 500 to Sanofi-Aventis and received an upfront payment of USD 50 Mn and a milestone payment of USD 5 Mn in May 2014 


Out-licensing deal for its first-in-class molecule GRC 15300

Glenmark entered into an out-licensing deal with Sanofi-Aventis for its molecule GRC 15300, a first-in-class TRPV3 antagonist. Glenmark received an upfront payment of USD 25 million


Out-licensing deal with Eli Lilly

Eli Lilly acquired the rights to a portfolio of TRPV1 antagonist molecules developed by Glenmark. Glenmark received an upfront fee of USD 45 Mn


Commenced research in novel biologics

To focus on development of novel biologics, Glenmark established its first R&D center for NBE research in Switzerland.

Out-licensing deal for novel molecule Melogliptin

Glenmark entered into an out-licensing deal with Merck KGaA for its molecule Melogliptin and received a total payment of USD 31 million.


Expanded operations to the US market

Glenmark launched front-end commercial sales in the US in 2005. To support its US operations with high quality products, it set up a manufacturing facility built to US FDA specifications at Goa, India.


Out-licensing deal for novel molecule Oglemilast

Glenmark entered into a deal with Teijin Pharma for the Japan rights of its molecule Oglemilast for which it received an upfront payment of USD 6 Mn


Glenmark’s first out-licensing deal

Glenmark created history where it sealed its first out-licensing deal with Forest Laboratories for GRC 3886. Glenmark received USD 35Mn as upfront and milestone payments


Diversified to API manufacturing

Glenmark forayed into manufacturing of APIs and commenced operations at the Kurkumbh API manufacturing facility in Maharashtra. In the following year expanding further, Glenmark also acquired API manufacturing facility at Ankleshwar, Gujarat.


Adding value to our stakeholders

Glenmark was first listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) of India at a market capitalization of $40 million.


Glenmark commissioned the Sinnar R&D centre in Maharashtra


The first successes

Glenmark entered the dermatology market with the launch of ‘Candid cream’.

Dermatology is a key focus area for Glenmark even today, for both formulations and novel drug discovery worldwide.


Touching lives of patients for over three decades

Glenmark was established in 1977 by our Founder Emeritus Late Mr. Gracias Saldanha.